

REMARKS

Applicants have amended claims 1-16. Attached hereto is a marked-up version of the changes made by the current amendments, captioned "Appendix to Amendment." The amended claims find support in the claims as originally filed and throughout the specification, and thus no new matter has been added. Claims 1-16 are pending.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: November 26, 2002

By: Rebecca M. McNeill  
Rebecca M. McNeill  
Reg. No. 43,796

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

## APPENDIX TO THE AMENDMENT

1. (Twice Amended) A method of preventing or treating at least one symptom of therapeutic agent for drug-resistant hypercalcemia comprising administering to a patient at least one substance ~~an active ingredient~~ that inhibits the binding between PTHrP and a receptor thereof.
2. (Twice Amended) The method ~~therapeutic agent~~ according to claim 1, wherein the drug-resistant hypercalcemia is resistant to a therapeutic agent for hypercalcemia other than said at least one substance ~~an active ingredient~~ that inhibits the binding between PTHrP and a receptor thereof.
3. (Twice Amended) The method ~~therapeutic agent~~ according to claim 1 or 2, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.
4. (Amended) The method ~~therapeutic agent~~ according to claim 1 or 2, wherein the therapeutic agent for hypercalcemia is a bone resorption-inhibiting agent.
5. (Twice Amended) The method ~~therapeutic agent~~ according to claim 4, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.
6. (Twice Amended) The method ~~therapeutic agent~~ according to any one of claims 1 or 2, wherein said at least one substance ~~the active ingredient~~ is an antagonist of ~~for~~ the PTHrP receptor.

7. (Twice Amended) The method ~~therapeutic agent~~ according to any one of claims 1 or 2, wherein said at least one substance ~~the active ingredient~~ is an anti-PTHrP antibody.

8. (Twice Amended) The method ~~therapeutic agent~~ according to any one of claims 1 or 2, wherein said at least one substance ~~the active ingredient~~ is a fragment of an anti-PTHrP antibody and/or a modified form of the fragment.

9. (Amended) The method ~~therapeutic agent~~ according to claim 7, wherein the antibody is monoclonal.

10. (Twice Amended) The method ~~therapeutic agent~~ according to claim 7, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

11. (Amended) The method ~~therapeutic agent~~ according to claim 7, wherein the antibody is in a humanized form.

12. (Amended) The method ~~therapeutic agent~~ according to claim 11, wherein the humanized antibody is humanized #23-57-137-1 antibody.

13. (Twice Amended) The method ~~therapeutic agent~~ according to any one of claims 1 or 2, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

14. (Amended) The method ~~therapeutic agent~~ according to claim 5, wherein said at least one substance ~~the active ingredient~~ is chosen from at least one of

- b) an antagonist of ~~for~~ the PTHrP receptor;
- b) an anti-PTHrP antibody; and
- c) a fragment of an anti-PTHrP antibody ~~and/or~~ a modified form of the fragment.

15. (Amended) The method ~~anti-PTHrP antibody~~ of claim 14, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

16. (Amended) The method ~~therapeutic agent~~ according to claim 5, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com